Market Cap 7.41B
Revenue (ttm) 7.80B
Net Income (ttm) 169.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 10.49
Profit Margin 2.18%
Debt to Equity Ratio 1.21
Volume 558,600
Avg Vol 939,212
Day's Range N/A - N/A
Shares Out 687.56M
Stochastic %K 74%
Beta 0.56
Analysts Sell
Price Target $12.15

Company Profile

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clo...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 34 935 712 200
Fax: 34 938 008 000
Address:
Avinguda de la Generalitat 152-158, Parque Empresarial Can Sant Joan Sant Cugat del Valles, Barcelona, Spain
Doozio
Doozio Aug. 2 at 6:15 PM
$GRFS dips appears a 🎁 during 🐒🍌🧠⏰♾️
0 · Reply
RunnerSignals
RunnerSignals Jul. 29 at 9:07 PM
$CELC $GRFS $HIMS $ECX $ODP Comeback Kings shook off the midday dips and closed strong
0 · Reply
DonCorleone77
DonCorleone77 Jul. 29 at 5:17 PM
$GRFS Grifols reports Q2 revenue EUR 1.89B vs. EUR 1.79B last quarter -- Q2 profit EUR 191M vs. EUR 115M last quarter. -- Reinstates dividend of EUR 0.15 per share -- Affirms 2025 guidance from capital markets day
0 · Reply
BeefStewart
BeefStewart Jul. 17 at 8:14 PM
$CERS Looks like some plasma-related stocks are just lagging $ADMA $GRFS ....
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 9:07 PM
$GRFS Grifols paid a higher price to buy blood plasma from an entity linked to its controlling family than from third-party suppliers, according to a regulator’s findings submitted in a court case ….
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 6:59 AM
$GRFS Grifols pagó hasta un 39% más para comprar plasma a Scranton Según las conclusiones de un regulador presentadas en un caso judicial, la farmacéutica española también acordó pagar a Scranton un margen fijo del 16,5% sobre los costes Bad news
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 23 at 8:15 PM
$GRFS bad news ? Weird day
0 · Reply
JarvisFlow
JarvisFlow Jun. 17 at 1:00 PM
JP Morgan updates rating for Grifols ( $GRFS ) to Neutral, target set at 7.6 → 10.3.
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 11:14 AM
$GRFS U.S. court rules to go on with Grifol lawsuit against Gotham City, Reuters says A New York court has found enough evidence to continue with the defamation lawsuit filed by Grifols against short seller Gotham City Research, Reuters reports. The Federal District Court for the Southern District of New York rejected Gotham City's request to dismiss the lawsuit, but did narrow it by rejecting some claims.
0 · Reply
ZacksResearch
ZacksResearch May. 28 at 2:57 PM
After a strong start, is $ADMA still the best bet, or is $GRFS taking the lead? 🏆 💡 ADMA boasts robust Asceniv demand and 15.9% gains in 2025, but trades at a pricey 25.48X forward earnings. 📈 Meanwhile, GRFS, with its wider portfolio and Zacks Rank #2 (Buy), offers a cheaper 7.19X valuation and a significant EPS improvement of 296% in 2025. Discover which stock could be your next winner 👉 https://www.zacks.com/commentary/2478303/adma-biologics-vs-grifols-which-plasma-therapy-stock-is-the-better-buy?cid=sm-stocktwits-2-2478303-body&ADID=SYND_STOCKTWITS_TWEET_2_2478303_BODY
0 · Reply
Latest News on GRFS
Grifols: If This Works Out, It Has Massive Upside

May 22, 2025, 12:09 PM EDT - 2 months ago

Grifols: If This Works Out, It Has Massive Upside


Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript

May 12, 2025, 4:51 PM EDT - 3 months ago

Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript


Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale

Feb 27, 2025, 12:58 PM EST - 5 months ago

Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale


Grifols expects to boost revenue and free cash flow, shares soar

Feb 27, 2025, 11:23 AM EST - 5 months ago

Grifols expects to boost revenue and free cash flow, shares soar


Grifols' sales rise over 10% in 2024, above target

Feb 26, 2025, 12:18 PM EST - 5 months ago

Grifols' sales rise over 10% in 2024, above target


Flat Footed Calls for Prompt Governance Overhaul at Grifols

Dec 10, 2024, 12:23 PM EST - 8 months ago

Flat Footed Calls for Prompt Governance Overhaul at Grifols


Grifols: More Attractive Than In A Very Long Time

Nov 29, 2024, 12:30 PM EST - 8 months ago

Grifols: More Attractive Than In A Very Long Time


Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?

Nov 29, 2024, 9:29 AM EST - 8 months ago

Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?


Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down

Oct 3, 2024, 5:20 PM EDT - 10 months ago

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down


Significant Shareholders Exercise Right to Grifols Board Seat

Sep 19, 2024, 3:23 PM EDT - 11 months ago

Significant Shareholders Exercise Right to Grifols Board Seat


Doozio
Doozio Aug. 2 at 6:15 PM
$GRFS dips appears a 🎁 during 🐒🍌🧠⏰♾️
0 · Reply
RunnerSignals
RunnerSignals Jul. 29 at 9:07 PM
$CELC $GRFS $HIMS $ECX $ODP Comeback Kings shook off the midday dips and closed strong
0 · Reply
DonCorleone77
DonCorleone77 Jul. 29 at 5:17 PM
$GRFS Grifols reports Q2 revenue EUR 1.89B vs. EUR 1.79B last quarter -- Q2 profit EUR 191M vs. EUR 115M last quarter. -- Reinstates dividend of EUR 0.15 per share -- Affirms 2025 guidance from capital markets day
0 · Reply
BeefStewart
BeefStewart Jul. 17 at 8:14 PM
$CERS Looks like some plasma-related stocks are just lagging $ADMA $GRFS ....
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 9:07 PM
$GRFS Grifols paid a higher price to buy blood plasma from an entity linked to its controlling family than from third-party suppliers, according to a regulator’s findings submitted in a court case ….
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 6:59 AM
$GRFS Grifols pagó hasta un 39% más para comprar plasma a Scranton Según las conclusiones de un regulador presentadas en un caso judicial, la farmacéutica española también acordó pagar a Scranton un margen fijo del 16,5% sobre los costes Bad news
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 23 at 8:15 PM
$GRFS bad news ? Weird day
0 · Reply
JarvisFlow
JarvisFlow Jun. 17 at 1:00 PM
JP Morgan updates rating for Grifols ( $GRFS ) to Neutral, target set at 7.6 → 10.3.
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 11:14 AM
$GRFS U.S. court rules to go on with Grifol lawsuit against Gotham City, Reuters says A New York court has found enough evidence to continue with the defamation lawsuit filed by Grifols against short seller Gotham City Research, Reuters reports. The Federal District Court for the Southern District of New York rejected Gotham City's request to dismiss the lawsuit, but did narrow it by rejecting some claims.
0 · Reply
ZacksResearch
ZacksResearch May. 28 at 2:57 PM
After a strong start, is $ADMA still the best bet, or is $GRFS taking the lead? 🏆 💡 ADMA boasts robust Asceniv demand and 15.9% gains in 2025, but trades at a pricey 25.48X forward earnings. 📈 Meanwhile, GRFS, with its wider portfolio and Zacks Rank #2 (Buy), offers a cheaper 7.19X valuation and a significant EPS improvement of 296% in 2025. Discover which stock could be your next winner 👉 https://www.zacks.com/commentary/2478303/adma-biologics-vs-grifols-which-plasma-therapy-stock-is-the-better-buy?cid=sm-stocktwits-2-2478303-body&ADID=SYND_STOCKTWITS_TWEET_2_2478303_BODY
0 · Reply
ZacksResearch
ZacksResearch May. 28 at 1:06 PM
At current levels, $GRFS scores over $ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum. Explore further: https://www.zacks.com/stock/news/2478303/adma-biologics-vs-grifols-which-plasma-therapy-stock-is-the-better-buy?cid=sm-stocktwits-2-2478303-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2478303_TEASER
0 · Reply
RunnerSignals
RunnerSignals May. 22 at 9:39 PM
Fresh Upgrades and Downgrades After-Hours! $CR $INGN $GRFS $MU $SWK and more in play! Analysts reshuffled the deck - who's your pick going into Friday? stocksrunner.com/news/2025-05-22-thursday-analyst-upgrades-and-downgrades
0 · Reply
Messerschmittbf109
Messerschmittbf109 May. 10 at 6:04 AM
$GRFS bad candle last session
0 · Reply
Biotekman
Biotekman Apr. 17 at 3:43 PM
$GRFS Just initiated a position. They have a "2029 plan" to reduce the debt. Promising.
2 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 15 at 6:44 PM
$GRFS take over soon
0 · Reply
LewisWay
LewisWay Apr. 15 at 3:59 PM
$GRFS 🤫🤩 Holly s... check this out... I remember what they've did last time, it's a retail war against hedge funds... I'm in. BUY BUY BUY 🥳🤛🧨🚀🚀🚀
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 14 at 8:10 PM
$GRFS $JSPR take over .. this is the end of
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 14 at 7:31 PM
$GRFS over SMA.
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 14 at 5:56 PM
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 14 at 5:55 PM
$JSPR $GRFS next to takeover (opa) soon Under real value from months
0 · Reply
DonCorleone77
DonCorleone77 Apr. 2 at 10:48 AM
$GRFS Grifols clarifies no knowledge of restarted discussion on offer from Brookfield Pursuant to the provisions of Article 227 of Law 6/2023 of March 17, on Securities Markets and Investment Services, Grifols, S.A. hereby informs about the following: With respect to information published in certain media outlet regarding discussions having restarted with respect to a potential new offer for Grifols' shares from Brookfield Capital Partners Limited, the Company informs that its Board of Directors has no knowledge regarding this information.
0 · Reply
wallstengine
wallstengine Apr. 2 at 10:19 AM
Brookfield has restarted talks with the Grifols family $GRFS over a potential offer for the Spanish blood-plasma firm, after walking away from a deal last year. No formal bid yet, but discussions are back on.
0 · Reply